MiLaboratories

MiLaboratories has emerged as a key player in the Biotechnology sector with its leading software platform, MiXCR. Founded in 2021 and headquartered in the United States, the company is dedicated to enhancing immune repertoire profiling through the analysis of Next-Generation Sequencing (NGS) data.

MiXCR has gained substantial traction in the industry, being the preferred choice for immune system studies by 8 out of 10 Big Pharma companies. Its applications span critical areas such as vaccine development, CAR-T therapies, and antibody discovery. The company also furthers scientific advancement by providing free access to its platform for academic and non-commercial use.

In its last funding round on February 17, 2022, MiLaboratories secured a $2.36M Seed Round investment from notable investors, Speedinvest and Acrobator Ventures, underlining strong confidence in its potential to revolutionize immune system research.